Table 1.
Cardiovascular complications in patients with SARS-CoV-2 infections.
| Cohort | Cao et al. | Wang et al. | Arentz et al. | Huang et al. | Yang et al. |
|---|---|---|---|---|---|
| No. of patients | 199 | 36 | 21 | 13 | 52 |
| Age, years | 58.0 (49.0–68.0) | 66 (57–78) | 70(43–92) | 49.0(41–61) | 59.7-13.3 |
| Sex ratio (F:M) | 79:120 | 14:22 | 10:11 | 2:11 | 17:35 |
| APACHE II | - | 17 (10–22) | - | - | 17(14-19) |
| SOFA | - | 5 (3–6) | - | - | - |
| Cardiovascular disease | - | 21 (58%) | 9 (43%) | 3 (13%) | 5 (10%) |
| Hypertension | - | 9 (25%) | - | 2 (15%) | - |
| Endocrine disease | 23 (12%) | 8 (22%) | 7 (33%) | 1(8%) | 9 (17%) |
| Cardiovascular complications | |||||
| Use of vasopressors | 44 (22%) | - | 14(67%) | 18 (35%) | |
| Shock | 4 (2%) | 11 (31%) | - | 3 (23%) | - |
| Myocardial injury | - | 8 (22%) | 7 (33%) | 4 (31%) | 12 (23%) |
| Arrhythmia | 1(0.5%) | 16 (44%) | - | - | - |
| Acute heart failure | 1(0.5%) | - | 4(19.1) | - | - |
| Use of ECMO | 4 (2%) | 4 (11%) | - | 2 (15%) | 6 (12%) |
| Mortality | 44 (22%) | 11 (31%) | 11(52%) | 6 (46%) | 32 (62%) |